Finance
2025.09.19
Lumosa Submits LT3001 Phase 3 Trial Consultation to the US FDA
Finance
2025.04.21
Lumosa Licenses the “T-Cell Enhancement Technology” from UNC
Finance
2025.03.10
Lumosa Ends Phase 2 Trial Early to Facilitate EOP2 Meeting for LT3001 with US FDA
Finance
2024.12.05
Media Report Clarification
Finance
2024.12.03
Media Report Clarification
Finance
2024.11.29
Lumosa Announces Details of Upcoming Institutional Investor Conference